Search results
5 dni temu · Fitzsimons et al. present a comprehensive pan-cancer single-cell RNA-seq atlas of intratumoral B cells, identifying ten distinct B and plasma cell clusters. They uncover associations with checkpoint inhibitor therapy response, explore B-T cell crosstalk, validate findings with spatial data, and offer an interactive tool for further research.
15 lis 2022 · We report the efficacy and cost-effectiveness of axi-cel compared to standard chemoimmunotherapy regimens in high-risk LBCL. Materials & Methods: We searched articles from PubMed, Embase, WebofScience, and Cochrane from the date of inception till 7/10/2022.
31 maj 2022 · This is a new avenue of B-cell-based immunotherapy, which is cost effective, safe, and makes use of polyclonal antibody responses. It involves the use of the chimeric B-cell epitope peptide receptor along with the T-cell epitope. Examples of B-cell peptide epitopes include various tyrosine kinases, such as VEGF, HER-1, HER-3, and IGF-1R . An ...
22 sie 2024 · CD19-targeted chimeric antigen receptors (CAR) T cells are one of the most remarkable cellular therapies for managing B cell malignancies. However, long-term disease-free survival is still a challenge to overcome.
22 gru 2022 · Key Points. Pola-R-CHP is provisionally cost-effective compared with R-CHOP for the frontline treatment of DLBCL at a WTP of $150 000/QALY. The cost-effectiveness of pola-R-CHP depends on its long-term outcomes (5-year PFS of at least 66.1% needed to remain cost-effective).
Recent reports of B cell depletion with novel chimeric antigen receptor (CAR) T cell approaches in an expanding number of autoimmune diseases highlight the potential role of B cell depletion in resetting immune tolerance.
2 mar 2024 · Abstract. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still a potentially curative option for B-cell Non-Hodgkin Lymphoma (B-NHL) in the modern immunotherapy era. The objective of this study was to analyze long-term outcomes of patients with B-NHL who received allo-HSCT.
